Veracyte/$VCYT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Ticker
$VCYT
Sector
Primary listing
Employees
824
Headquarters
Website
Veracyte Metrics
BasicAdvanced
$3.3B
109.62
$0.38
1.86
-
Price and volume
Market cap
$3.3B
Beta
1.86
52-week high
$47.32
52-week low
$22.61
Average daily volume
956K
Financial strength
Current ratio
6.226
Quick ratio
5.741
Long term debt to equity
2.876
Total debt to equity
3.217
Interest coverage (TTM)
27,822.50%
Profitability
EBITDA (TTM)
78.015
Gross margin (TTM)
70.98%
Net profit margin (TTM)
6.12%
Operating margin (TTM)
11.24%
Effective tax rate (TTM)
2.23%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
2.46%
Return on equity (TTM)
2.49%
Valuation
Price to earnings (TTM)
109.616
Price to revenue (TTM)
6.585
Price to book
2.61
Price to tangible book (TTM)
8.25
Price to free cash flow (TTM)
33.201
Free cash flow yield (TTM)
3.01%
Free cash flow per share (TTM)
1.256
Growth
Revenue change (TTM)
16.41%
Earnings per share change (TTM)
-409.31%
3-year revenue growth (CAGR)
20.42%
10-year revenue growth (CAGR)
26.37%
3-year earnings per share growth (CAGR)
-14.37%
10-year earnings per share growth (CAGR)
-12.02%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Bulls say / Bears say
Testing revenue rose 17% year-over-year to $128 million in Q3 2025, fueled by a 19% increase in testing volume to 43,700 tests, reflecting strong and steady demand for Veracyte’s diagnostic products. (Investing.com)
Decipher Prostate test volume hit 26,700 tests in Q3 2025, marking the fourteenth consecutive quarter of over 25% year-over-year growth and signaling growing clinical adoption. (Investing.com)
Veracyte increased profitability with an adjusted EBITDA margin of 30% in Q3 2025, up from 27.5% in Q2, indicating stronger operating leverage as revenues grow. (Investing.com)
Veracyte posted a GAAP net loss of $1.0 million in Q2 2025, mainly due to a $20.5 million non-cash impairment charge tied to the sale and liquidation of its French subsidiary. (Investing.com)
Afirma thyroid test volume increased just 8% year-over-year in Q2 2025 to about 16,950 tests, well below Decipher’s 28% growth and emphasizing product concentration risk. (Investing.com)
Product revenue dropped 8% year-over-year to $3.6 million in Q2 2025, highlighting inconsistent performance in Veracyte’s ancillary diagnostic segments. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Veracyte News
AllArticlesVideos
Veracyte to Participate in Upcoming Investor Conferences
Business Wire2 days ago
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
Business Wire4 days ago
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $3.3B as of November 08, 2025.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 109.62 as of November 08, 2025.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.